Pasithea Therapeutics Corp. Overview
Pro stress-test →Pasithea is a biotechnology company primarily focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders and RASopathies. The company's lead therapeutic candidate is PAS-004, a next-generation macrocyclic MEK inhibitor for potential use in neurofibromatosis type 1–associated plexiform neurofibromas and certain oncology indications.
Strategic Profile
Pro stress-test →PAS-004 is being developed to treat a range of RASopathies, including neurofibromatosis type 1 (NF1), MAPK pathway-driven tumors, and ETS2 driven diseases including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. Pasithea appointed Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer effective May 1, 2026.
Competitive Landscape
Pro stress-test →Pasithea competes in the specialized RASopathy and CNS disorder treatment space against other biotech companies developing MEK inhibitors and novel neurological therapeutics. The company's focus on rare genetic disorders and neuro-inflammatory conditions positions it in less crowded segments compared to larger oncology-focused competitors, though development timelines remain lengthy.
Industry Context
Pasithea Therapeutics Corp. operates in Clinical-stage biotechnology - rare genetic disease therapeutics.
Key facts
Founded: 2020 · Headquarters: Miami Beach, FL · Employees: 5 · Revenue: $0M · Market cap: N/A